Background: Genetic risk stratification may inform decisions of whether-and when-a man should undergo prostate cancer (PCa) screening. We previously validated a polygenic hazard score (PHS), a weighted sum of 54 single-nucleotide polymorphism genotypes, for accurate prediction of age of onset of aggressive PCa and improved screening performance. We now assess the potential impact of PHS-informed screening.
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Introduction
Prostate cancer (PCa) is the second-most-common malignancy in men worldwide with nearly 1.3 million cases diagnosed globally in 2018 alone 1 . PCa was the third leading cause of European male cancer mortality in 2018, following mortality from lung and colorectal cancers 2 .
PCa screening with prostate-specific antigen (PSA) testing can reduce mortality 3 , but universal screening may result in the overdetection of cancers that would never become clinically apparent in a man's life-time and overtreatment of indolent disease. Guidelines recommend that individual men participate in informed decision making about screening, taking into account factors such as their age, race/ethnicity, family history, and preferences 4-6 .
Assessment of a man's genetic risk of developing PCa has promise for guiding individualized screening decisions 7, 8 . We previously developed a polygenic hazard score (PHS) as a weighted sum of 54 single-nucleotide polymorphism (SNP) genotypes using clinical and genetic data from 31,747 men 9 . Validation testing, performed in an independent dataset consisting of 6,411 men from the United Kingdom (UK) ProtecT study 10, 11 , showed the PHS to be a significant predictor of age at diagnosis of aggressive PCa, defined as cases where any of the following applied: Gleason score ≥ 7, clinical stage T3-T4, PSA ≥ 10, or where there were nodal or distant metastases 9 . Risk stratification by the PHS also improved the screening performance of PSA testing; the positive predictive value of PSA testing for aggressive PCa increased as PHS increased 9 .
Here, we apply the PCa PHS to population data to assess its potential impact on individualized screening. Specifically, we combine genetic risk, measured by PHS, and known population incidence rates to estimate a risk-equivalent age: e.g. the age at which a man with a given PHS will have the same risk of higher-grade PCa as a typical man at age 50 years. Such genetic risk estimates can guide individualized decisions about whether-and at what age-a man might benefit from PCa screening.
Methods

Polygenic hazard score (PHS)
Full methodologic details of the development and validation of the PCa PHS have been described previously 9 . Briefly, the PHS was created using data from men of European ancestry as a continuous survival analysis model 12 to predict the age of PCa onset. PHS was calculated as the vector product of a patient's genotype (X i ) for n selected SNPs and the corresponding parameter estimates (β i ) from a Cox proportional hazards regression (equation 1):
The 54 SNPs included in the model, and their parameter estimates, have been published 9 .
Population age-specific incidence Age-specific PCa incidence data were obtained for men aged 40-70 years from the United Kingdom, 2013-2015 (Cancer Research UK) 13 . Men may be less likely to receive PCa screening outside this age range 3, 14 . The log of the PCa incidence data were fit using linear regression to develop a continuous model of age-specific PCa incidence in the UK (h all ). 
As described in the original validation of this PHS model for PCa 9 , PHS calculated in the ProtecT dataset will be biased by the disproportionately large number of cases included, relative to incidence in the general population. Leveraging the cohort design of the ProtecT study 10 , we therefore applied a correction for this bias, using previously published methods 18 Finally, we considered the common clinical scenario of a man presenting to his primary care physician (PCP) to discuss PCa screening. To illustrate how PHS might influence this discussion, we identified the subset of 945 men in the ProtecT validation dataset who were around the median age of 60 years (57-63), to represent a typical patient. From this subset, we created three groups: those whose PCa risk-equivalent age remained within the selected range (ages 57-63), those whose risk-equivalent age was <57, and those whose risk-equivalent age was >63. We then calculated the positive predictive value (PPV) of PSA testing for these three groups using methods described previously 9 ; a true positive PSA was defined as biopsy-detected PCa (biopsy was indicated for men with PSA≥3.0 ng/mL). We calculated the PPV (and standard error [SE] of the mean) for PSA testing in the three PHS-adjusted (PCa risk-equivalent age) groups by taking 1,000 random samples of cases in the dataset, matching the ratio of controls to cases in ProtecT.
Results
Linear regression yielded a model of PCa age-specific incidence rates (equation 5, R 2 =0.96 and p=0.001) that was highly consistent with empirical data reported by Cancer
Research UK (Figure 1) .
h all = 0.004e 0.203(age-40)
In the CAP study (of low-intensity PCa screening in the UK population) 15 
Discussion
We demonstrate the application of the PHS to population, age-specific incidence data to estimate age-specific risk of higher-grade PCa. The resulting age-specific hazard functions (displayed as survival curves in Figure 2 ) demonstrate clinically-meaningful differences across various levels of genetic risk (estimated by PHS shown to be a more accurate predictor of age of aggressive PCa onset than patient-provided family history 9, 22 . PHS, in conjunction with other informative factors such as family history, may help identify men who may develop those cancers that can cause morbidity and mortality 11 .
The stratification of men based on their genetic risk is of particular interest in the primary care setting, where the majority of PCa screening discussions take place. Shared decision-making between patient and physician has long been recommended in discussions of PCa screening 5, 23 ,
and PCPs are tasked with determining an individual's risk based on factors such as his family history and ethnicity. However, physicians demonstrate different attitudes towards screening, with some screening all men proactively to avoid underdiagnoses, some screening only those men who request it, and some who attempt to weigh the costs and benefits of PSA screening on a case-by-case basis 24, 25 . PCPs, who are already limited by time constraints and their patients' other health issues, must carefully discuss the complex risks and benefits of PSA screening with their patients 26 .
Quantitative risk stratification could guide physicians in their screening conversations with patients by providing an objective risk-equivalent age for the development of higher-grade or other aggressive disease. This allows for simpler and more standardized informed decision- Cost-effectiveness is another concern regarding PCa screening. Use of PHS, a one-time test valid for a man's entire life, can improve screening efficiency while reducing overall costs.
The genotyping chip assay requires only a saliva sample and can be run for costs similar to those for single-gene testing (e.g. the BRCA mutation). Genotyping also informs genetic risks for other diseases, possibly allowing multiple tests to be run on the same genotype results 27, 28 . PSA screening (and subsequent prostate biopsy) could be offered only to those men at higher risk of aggressive PCa. PHS could increase the efficiency of any PCa screening program by incorporating knowledge that there are some men with higher baseline genetic risks of developing higher-grade PCa, even at a relatively young age, while others have a low baseline genetic risk.
Limitations of this work include that the PHS did not incorporate genotypic data from men of non-European ancestry during its development 9 , a reflection of the available data, which may affect the use of the PHS for screening decision-making in men from other ethnic groups. This is noteworthy, as disparities in PCa incidence and survival show that in the USA, men with African ancestry are more likely to develop PCa and to die from their disease 29 . Our group and others are studying the application of genetic scores to non-European ethnic groups.
Additionally, there are now over 140 SNPs reported to have associations with PCa, identified using a meta-analysis that included ProtecT data 30 [7, 11] α Risk of typical 50-year-old defined as overall population incidence at age 50. β ΔAge was defined as the difference (rounded to the nearest integer) between 50 and the age when risk is that of a typical 50-year-old man. Figure 1 . Annual incidence of prostate cancer in the United Kingdom, 2013-2015. Dots represent the raw, age-specific incidence rates of each age range, per 100,000 males. The black line represents the results of linear regression for an exponential curve to give a continuous model of age-specific incidence in the United Kingdom, R 2 =0.96, p=0.001. Figure 2 . Survival free of higher-grade prostate cancer, as derived from application of polygenic hazard score (PHS) hazard ratios and population data from the United Kingdom. The overall population incidence is taken as the median risk (50 th percentile); this accounts for age-specific proportions of prostate cancer that was high grade in the CAP trial 15 . Hazard ratios were calculated within ProtecT data for various levels of genetic risk (i.e., PHS percentiles: 1, 5, 20, 80, 95, and 99) and used to adjust the median risk curve. Blue lines represent genetic risk lower than the median while red lines represent genetic risk higher than the median.
ic Figure 3 . Application of prostate cancer risk-equivalent age to the clinical scenario of whether to screen a 60-year-old man (median age from ProtecT). The risk-equivalent age is the patient's true age adjusted by PHS level. This plot shows results for all men from ProtecT aged approximately 60 years old (range: 57-63), grouped by their calculated prostate cancer riskequivalent age: <57, 57-63, or >63. The positive predictive value (PPV) and the corresponding standard errors of the mean of PSA testing is shown for each of these 3 groups. The dashed, grey-line shows the expected PPV for PSA testing based on a published pooled analysis 5 .
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